Two posters highlighted the effects of sacubitril/valsartan (Entresto; Novartis) on key biomarkers and cardiac function in ...

The emergence of new therapies for heart failure with reduced ejection fraction (HFrEF) present significant advances in the management of patients with HFrEF. They also present new questions and ...

Heart failure specialists finally have data to back up their long-standing suspicions that clinical inertia is to blame for the underuse of the four-pillar treatment approach for patients who have ...

http://orcid.org/0000-0003-1053-7840Paul M Haydock, http://orcid.org/0000-0002-8126-9583Andrew S Flett To review the pathophysiology of heart failure with reduced ...

Catheter ablation is associated with significant reductions in AF symptoms, AF-related hospitalization, and HF symptoms across HF subtypes.

HFrEF occurs when left ventricular ejection fraction (LVEF) is reduced to 40% or less. The European Society of Cardiology estimates that in people with heart failure, around 60% have HFrEF [2].

Inhibitors of the renin–angiotensin–aldosterone (RAAS) system are cornerstones of the management of patients with heart failure with reduced left ventricular ejection fraction (HFrEF). However, RAAS ...